1722 checks reveal why one global peptide verdict fails.
We analyzed 41 tracked peptide and drug names across 42 countries. The resulting index connects each name to a resolved identity, a national product record, and a separate seller or supply record. It measures verification coverage, not medical suitability or a blanket legal conclusion.
41 named compounds repeated across the same 42 destination-country framework.
Every row carries identity, product, and seller or supply routes. 71 additional routes support sourced compound-country statuses.
27 identity sources plus 42 product and 42 seller or supply sources, with separate exact status evidence where available.
English, Spanish, Arabic, Dutch, German, Brazilian Portuguese, Danish, European Portuguese, Finnish, French, Indonesian, Italian, Japanese, Korean, Polish, Simplified Chinese, Swedish, Thai, Traditional Chinese (Hong Kong), Traditional Chinese (Taiwan), Turkish, and Vietnamese.
The record type changes the answer.
Every number below is computed from the public 1722-row dataset. Change the source records and the report changes with them.
Research-market identities are the largest lane.
840 rows map to research price boards, 546 map to clinical pipeline profiles, and 294 map to product-specific medicine records. A separate 42-row FDA-reviewed KPV lane keeps that unapproved peptide record out of all three categories.
Identity, product, and seller are three different questions.
The index contains 27 identity sources, 42 national product routes, and 42 seller or supply routes. A match in one lane does not prove the other two.
Europe now leads regional coverage.
656 rows cover 16 European countries and 574 cover 14 Asia-Pacific countries. They represent 38.1% and 33.3% of the index respectively, but the sources remain national because authorization, market status, pharmacy authority, and supply can diverge.
Every country receives the same 41-name test.
Each destination has 41 exact compound pages and 123 attached reference slots. This fixed design makes gaps visible without pretending unlike categories are comparable.
Five discovery regions. 42 national boundaries.
Regions organize the report. Countries remain the unit where the product and seller records must be checked.
Europe
656 compound-country rows
Open regional map ↗Asia-Pacific
574 compound-country rows
Open regional map ↗Latin America
205 compound-country rows
Open regional map ↗Middle East and Africa
205 compound-country rows
Open regional map ↗North America
82 compound-country rows
Open regional map ↗41 names, four evidence lanes.
Each name has 42 destination rows. The evidence lane determines what the identity record can and cannot support.
| Compound | Evidence lane | Countries | Exact pages | World map |
|---|---|---|---|---|
| Amycretin / Zenagamtide | Clinical pipeline profile | 42 | 42 | Open map ↗ |
| AOD-9604 | Research price board | 42 | 42 | Open map ↗ |
| BPC-157 | Research price board | 42 | 42 | Open map ↗ |
| Cagrilintide | Clinical pipeline profile | 42 | 42 | Open map ↗ |
| CagriSema | Clinical pipeline profile | 42 | 42 | Open map ↗ |
| CJC-1295 DAC | Research price board | 42 | 42 | Open map ↗ |
| CJC-1295 no DAC | Research price board | 42 | 42 | Open map ↗ |
| DSIP / Emideltide | Research price board | 42 | 42 | Open map ↗ |
| Ecnoglutide | Clinical pipeline profile | 42 | 42 | Open map ↗ |
| EGRIFTA WR | FDA-approved medicine | 42 | 42 | Open map ↗ |
| Eloralintide | Clinical pipeline profile | 42 | 42 | Open map ↗ |
| Enicepatide | Clinical pipeline profile | 42 | 42 | Open map ↗ |
| GHK-Cu | Research price board | 42 | 42 | Open map ↗ |
| IGF-1 LR3 | Research price board | 42 | 42 | Open map ↗ |
| Ipamorelin | Research price board | 42 | 42 | Open map ↗ |
| Kisspeptin-10 / KP-10 | Research price board | 42 | 42 | Open map ↗ |
| KPV | FDA-reviewed unapproved peptide identity | 42 | 42 | Open map ↗ |
| Liraglutide | FDA-approved medicine | 42 | 42 | Open map ↗ |
| MariTide | Clinical pipeline profile | 42 | 42 | Open map ↗ |
| Mazdutide | Clinical pipeline profile | 42 | 42 | Open map ↗ |
| Melanotan I | Research price board | 42 | 42 | Open map ↗ |
| Melanotan II | Research price board | 42 | 42 | Open map ↗ |
| MOTS-c | Research price board | 42 | 42 | Open map ↗ |
| NAD+ | Research price board | 42 | 42 | Open map ↗ |
| Orforglipron / Foundayo | FDA-approved medicine | 42 | 42 | Open map ↗ |
| Pemvidutide | Clinical pipeline profile | 42 | 42 | Open map ↗ |
| Petrelintide | Clinical pipeline profile | 42 | 42 | Open map ↗ |
| PT-141 / Bremelanotide | Research price board | 42 | 42 | Open map ↗ |
| Retatrutide | Clinical pipeline profile | 42 | 42 | Open map ↗ |
| SCENESSE | FDA-approved medicine | 42 | 42 | Open map ↗ |
| Selank | Research price board | 42 | 42 | Open map ↗ |
| Semaglutide | FDA-approved medicine | 42 | 42 | Open map ↗ |
| Semax | Research price board | 42 | 42 | Open map ↗ |
| Sermorelin | Research price board | 42 | 42 | Open map ↗ |
| Survodutide | Clinical pipeline profile | 42 | 42 | Open map ↗ |
| TB-500 | Research price board | 42 | 42 | Open map ↗ |
| Tesamorelin | Research price board | 42 | 42 | Open map ↗ |
| Thymosin Alpha-1 | Research price board | 42 | 42 | Open map ↗ |
| Tirzepatide | FDA-approved medicine | 42 | 42 | Open map ↗ |
| VK2735 | Clinical pipeline profile | 42 | 42 | Open map ↗ |
| VYLEESI | FDA-approved medicine | 42 | 42 | Open map ↗ |
Resolve, route, then compare.
- 01
Resolve the searched name.
Match the compound to a research-market record, an FDA-reviewed unapproved peptide identity, a sponsor-led clinical program, or an approved medicine reference. Similar naming does not merge the categories.
- 02
Choose the destination.
Use the country’s official product, medicine, or regulatory database. A record in another country is not a substitute for the destination record.
- 03
Verify the supplier separately.
Resolve the legal pharmacy, establishment, professional, seller, or supply identity behind the website. Branding and shipping language are discovery signals only.
- 04
Compare only like with like.
Price or availability comparisons require the same category, exact product, presentation, destination, seller identity, source date, and evidence boundary.
What 1722 checks do not prove.
This report does not provide a country-wide legal opinion, certify a seller, establish shipment eligibility, verify laboratory quality, or recommend medical use. Official records can change after the review date.
The analysis covers 41 tracked names and 42 countries. It is a transparent verification sample, not a census of every peptide, medicine, jurisdiction, product presentation, pharmacy, clinic, or research supplier.
Read the publication methodology →Submit a correction or press request →Quote the finding. Keep the source trail.
Use the report URL for narrative findings and the dataset landing page for row-level analysis. Both preserve the publication date, method, limits, and correction route.
Peptide Local Editorial Desk. “2026 Global Peptide Verification Index.” Published 2026-07-20. https://peptidelocal.com/reports/global-peptide-verification-index-2026
@report{peptide_local_2026_global_verification,
title = {2026 Global Peptide Verification Index},
author = {{Peptide Local Editorial Desk}},
institution = {Peptide Local},
year = {2026},
month = {July},
url = {https://peptidelocal.com/reports/global-peptide-verification-index-2026},
note = {Analysis of 1722 compound-country verification records}
}